You are here: Industry Insights > Novartis

News List

Novartis secures US rights to Adamis' epinephrine auto injector pharmafile
July 06, 2018
Under the agreement, the Swiss pharma firm will be awarded the rights to the 0.3mg and 0.15mg dosages of the product, subject to FDA approval.
CHMP recommends Novartis' CAR-T therapy Kymriah for EU approval pharmafile
July 06, 2018
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T therapy Kymriah (tisagenlecleucel, formerly CTL019).
Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month worldpharmanews
July 05, 2018
Novartis and the European Migraine and Headache Alliance (EMHA) announced initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries.
Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine worldpharmanews
July 05, 2018
Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin worldpharmanews
July 05, 2018
Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1].
CAR-T therapies leap towards EU approval pharmatimes
July 04, 2018
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig fiercepharma
July 04, 2018
Amgen and Novartis’ Aimovig, first in its new class of migraine meds, hit the scene in May. Patients were ready and waiting for it.
CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing fiercepharma
July 02, 2018
Months after Novartis and Gilead Sciences won their CAR-T approvals in the U.S., the companies have scored CHMP recommendations for Kymriah and Yescarta in Europe.
Merck and Novartis gender bias suits draw renewed attention, and New York is taking action fiercepharma
July 02, 2018
As the #MeToo movement puts workplace sexual harassment at the front, Merck & Co. and Novartis, two of the largest pharma companies, find themselves entangled in a different kind of gender problem: alleged pregnancy discrimination.
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page